Back to Results


Title Characterizing HIV-related Diastolic Dysfunction
Therapeutic Area Heart Failure, HIV/AIDS, Cardiovascular Disease, Cardiomyopathy, Cardiac Failure
Principal Investigator Gordon Huggins, MD
Min Age 40 Years
Gender All
Contact Nathan Yuen
617 636-4990
More Information


This is a multicenter clinical trial of a cross section of HIV+ patients with and without diastolic dysfunction. Approximately 200 HAART-treated virally suppressed HIV+ subjects (100 HIV+/DD+ & 100 HIV+/DD-) will be enrolled. Currently only accepted patients who have HIV and Diastolic Dysfunction. This study will evaluate biomarkers, phenomapping, metabolomics, cMRI, and echocardiography to determined characteristics unique to this patient population.

Study Details

Inclusion Criteria

  • On HAART for >6 months (HIV positive cohort only)
  • History of adequate viral suppression as defined by HIV RNA level <200 copies/mL in the past 6 months
  • LVEF >50%

Exclusion Criteria

  • Comorbid inflammatory disease (e.g. RA or SLE)
  • Chronic use of steroids or anti-inflammatory therapy
  • Active in a clinical trial with investigational product

Study Requirements

Screening Visit:
  • ECHO
Baseline Visit:
  • Medical History
  • Physical Exam
  • EKG
  • Blood Draw
  • cMRI
  • KCCQ
Research Visits: Usually 3 visits, however some are able do in two

Length of Participation: All Study procedures must be completed within 42 days from consenting.